In a phase IIb open-label trial of 240 healthy adolescents primed with BNT162b2, a PHH-1V protein booster produced higher Omicron BA.1 neutralising titres (measured in 90) than in young adults from an earlier trial, meeting non-inferiority; no related serious adverse events.
Clinical trialn = 240
Esteban Riera et al. Immunogenicity and Safety of PHH-1V COVID-19 Vaccine as a Heterologous Booster in Adolescents